| Deler fremragende | 3,207,810 shares |
| Insideraktier | 1.614.578 shares |
| Insider ejerskab | 50,33 % |
| Total Insiders | 33 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Passage Bio, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Kathleen Borthwick CFO - [O] | 5.402 | 5.402 | |
| Cale Edgar B. GC & Corporate Secretary - [O] | 45.995 | 2.300 | |
| William Chou PRESIDENT AND CEO, Director - [D] [O] | 6.524 | 6.524 | |
| Athena Countouriotis Director - [D] | 18.900 | 945 | |
|
Fhmls Ix, L.l.c.
10% Owner -
|
5.009.219 | 250.461 | |
|
Fhmls Ix, L.p.
10% Owner -
|
5.009.219 | 250.461 | |
| Mark S Forman CHIEF MEDICAL OFFICER - [O] | 48.631 | 2.432 | |
| Alexandros Fotopoulos Chief Technical Officer - [O] | 28.693 | 1.435 | |
|
Frazier Life Sciences IX, L.P.
10% Owner -
|
5.009.219 | 250.461 | |
| Bruce A Goldsmith CEO and President, Director - [D] [O] | 15.983 | 799 | |
|
Patrick J Heron
Director, 10% Owner -
[D]
|
5.009.219 | 250.461 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Saqib Islam Director - [D] | 5.000 | 250 | |
| Sandip Kapadia Director - [D] | 0 | 0 | |
| Simona King Chief Financial Officer - [O] | 23.994 | 1.200 | |
|
Lynx1 Capital Management LP
10% Owner -
|
623.704 | 623.704 | |
| Richard Steven Morris Chief Financial Officer - [O] | 5.454 | 273 | |
|
Orbimed Advisors Llc
10% Owner -
|
6.066.343 | 303.317 | |
|
OrbiMed Capital GP VII LLC
10% Owner -
|
6.841.423 | 303.317 | |
| Quigley Jill M. Chief Operating Officer - [O] | 368.754 | 18.438 | |
| Liam Ratcliffe Director - [D] | 2.800 | 140 | |
| Gary Romano Chief Medical Officer - [O] | 0 | 0 | |
| Stephen P Squinto Head of Research and Dev, Director - [D] [O] | 1.337.150 | 66.858 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Eliseo Oreste Salinas | 157.500 | ||
| Monika Maria Toernsen Chief Commercial Officer - [O] | 3.319 | 166 | |
|
James N Topper
10% Owner -
|
5.009.219 | 250.461 | |
|
Versant Vantage I GP, L.P.
10% Owner -
|
933.352 | 46.668 | |
|
Versant Vantage I GP-GP, LLC
10% Owner -
|
933.352 | 46.668 | |
|
Versant Vantage I, L.P.
10% Owner -
|
933.352 | 46.668 | |
|
Versant Venture Capital VI, L.P.
10% Owner -
|
933.352 | 46.668 | |
|
Versant Ventures VI GP, L.P.
10% Owner -
|
933.352 | 46.668 | |
|
Versant Ventures VI GP-GP, LLC
10% Owner -
|
933.352 | 46.668 | |
| Thomas Woiwode Director - [D] | 933.352 | 46.668 | |
| Tadataka Yamada Director - [D] | 656.149 | 32.807 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i PASG / Passage Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i PASG / Passage Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | 2026-01-08 | 4 | Chou William | PASG | Common Stock | D | 18,4394 | -4.076 | -75 | 6.524 | ||||
| 2026-01-12 | 2026-01-08 | 4 | Chou William | PASG | Common Stock | D | 10.000 | 10.600 | ||||||
| 2026-01-12 | 2026-01-08 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 18,4394 | -2.062 | -38 | 5.402 | ||||
| 2026-01-12 | 2026-01-08 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 5.000 | 7.464 | ||||||
| 2025-09-15 | 2025-09-15 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 6,9895 | 11.900 | 83 | 623.704 | ||||
| 2025-09-15 | 2025-09-12 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 6,9908 | 19.783 | 138 | 611.804 | ||||
| 2025-09-15 | 2025-09-11 | 4 | Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share (Common Stock) | I | 6,9558 | 325 | 2 | 592.021 | ||||
| 2025-07-24 | 2025-07-24 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 5,7127 | 66.423 | 379 | 591.696 | ||||
| 2025-07-24 | 2025-07-23 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 5,7408 | 49.302 | 283 | 525.273 | ||||
| 2025-07-24 | 2025-07-22 | 4 | Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share ("Common Stock") | I | 5,4361 | 13.123 | 71 | 475.971 | ||||
| 2025-06-26 | 2025-06-26 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3300 | -213.257 | -70 | 6.066.343 | ||||
| 2025-06-26 | 2025-06-25 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3300 | -138.800 | -46 | 6.279.600 | ||||
| 2025-06-26 | 2025-06-24 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3500 | -231.600 | -81 | 6.418.400 | ||||
| 2025-04-24 | 2025-04-24 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3200 | -68.195 | -22 | 6.650.000 | ||||
| 2025-04-24 | 2025-04-23 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3400 | -89.328 | -30 | 6.718.195 | ||||
| 2025-04-24 | 2025-04-22 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3400 | -78.049 | -27 | 6.807.523 | ||||
| 2025-04-17 | 2025-04-17 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3300 | -77.090 | -25 | 6.885.572 | ||||
| 2025-04-17 | 2025-04-16 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3300 | -61.638 | -20 | 6.962.662 | ||||
| 2025-04-17 | 2025-04-15 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,3800 | -10.326 | -4 | 7.024.300 | ||||
| 2025-02-12 | 2025-02-11 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 0,5296 | -3.183 | -2 | 41.283 | ||||
| 2025-02-12 | 2025-02-10 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 8.000 | 44.466 | ||||||
| 2025-01-14 | 2025-01-14 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,6000 | -79.024 | -47 | 7.034.626 | ||||
| 2025-01-14 | 2025-01-13 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,6400 | -17.986 | -12 | 7.113.650 | ||||
| 2025-01-14 | 2025-01-10 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,6600 | -126.209 | -83 | 7.131.636 | ||||
| 2025-01-08 | 2025-01-08 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,6800 | -75.007 | -51 | 7.257.845 | ||||
| 2025-01-08 | 2025-01-07 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7100 | -52.536 | -37 | 7.332.852 | ||||
| 2025-01-08 | 2025-01-06 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7700 | -19.481 | -15 | 7.385.388 | ||||
| 2024-12-31 | 2024-12-27 | 4 | Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share | I | 0,6451 | 373.645 | 241 | 9.256.953 | ||||
| 2024-12-26 | 2024-12-20 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,6000 | -230.321 | -138 | 7.404.869 | ||||
| 2024-12-11 | 2024-12-11 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8000 | -80 | -0 | 7.635.190 | ||||
| 2024-12-11 | 2024-12-10 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8000 | -8.015 | -6 | 7.635.270 | ||||
| 2024-12-11 | 2024-12-09 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8400 | -54.181 | -46 | 7.643.285 | ||||
| 2024-12-06 | 2024-12-06 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8200 | -20.903 | -17 | 7.697.466 | ||||
| 2024-12-06 | 2024-12-04 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7900 | -76.200 | -60 | 7.718.369 | ||||
| 2024-11-27 | 2024-11-27 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 0,6711 | 29.300 | 20 | 8.883.308 | ||||
| 2024-11-27 | 2024-11-26 | 4 | Lynx1 Capital Management LP | PASG | Common Stock | I | 0,7075 | 167.055 | 118 | 8.854.008 | ||||
| 2024-11-27 | 2024-11-25 | 4 | Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share ("Common Stock") | I | 0,5641 | 259.998 | 147 | 8.686.953 | ||||
| 2024-09-23 | 2024-09-19 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7100 | -39.300 | -28 | 7.794.569 | ||||
| 2024-09-18 | 2024-09-18 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7300 | -25.631 | -19 | 7.833.869 | ||||
| 2024-09-18 | 2024-09-17 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7300 | -111.400 | -81 | 7.859.500 | ||||
| 2024-09-18 | 2024-09-16 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,7400 | -63.100 | -47 | 7.970.900 | ||||
| 2024-08-09 | 3 | Lynx1 Capital Management LP | PASG | Common stock, $0.0001 par value per share | I | 8.426.955 | ||||||||
| 2024-02-13 | 2024-02-13 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 0,9700 | -1.470 | -1 | 28.466 | ||||
| 2024-02-13 | 2024-02-10 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 4.000 | 29.936 | ||||||
| 2024-02-13 | 2024-02-13 | 4 | Forman Mark S | PASG | Common Stock | D | 0,9700 | -1.638 | -2 | 48.631 | ||||
| 2024-02-13 | 2024-02-10 | 4 | Forman Mark S | PASG | Common Stock | D | 5.000 | 50.269 | ||||||
| 2024-01-03 | 2024-01-02 | 4 | Forman Mark S | PASG | Common Stock | D | 0,9100 | -15.813 | -14 | 45.269 | ||||
| 2024-01-03 | 2023-12-31 | 4 | Forman Mark S | PASG | Common Stock | D | 50.000 | 61.082 | ||||||
| 2024-01-03 | 2024-01-02 | 4 | Cale Edgar B. | PASG | Common Stock | D | 0,9100 | -15.813 | -14 | 45.995 | ||||
| 2024-01-03 | 2023-12-31 | 4 | Cale Edgar B. | PASG | Common Stock | D | 50.000 | 61.808 | ||||||
| 2024-01-03 | 2024-01-02 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 0,9100 | -10.672 | -10 | 25.936 | ||||
| 2024-01-03 | 2023-12-31 | 4 | Borthwick Kathleen | PASG | Common Stock | D | 30.000 | 36.608 | ||||||
| 2023-08-01 | 2023-07-28 | 4 | King Simona | PASG | Common Stock | D | 0,8800 | -11.453 | -10 | 23.994 | ||||
| 2023-08-01 | 2023-07-28 | 4 | King Simona | PASG | Common Stock | D | 31.250 | 35.447 | ||||||
| 2023-06-29 | 2023-06-28 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8400 | 575.195 | 483 | 8.034.000 | ||||
| 2023-06-29 | 2023-06-27 | 4 | ORBIMED ADVISORS LLC See footnotes | PASG | Common Stock | I | 0,8400 | 617.382 | 519 | 7.458.805 | ||||
| 2023-06-20 | 2023-06-16 | 4 | Fotopoulos Alexandros | PASG | Common Stock | D | 0,9325 | -4.052 | -4 | 28.693 | ||||
| 2023-06-20 | 2023-06-15 | 4 | Fotopoulos Alexandros | PASG | Common Stock | D | 12.500 | 32.745 | ||||||
| 2023-04-20 | 2023-04-18 | 4 | King Simona | PASG | Common Stock | D | 1,0500 | -2.053 | -2 | 2.053 | ||||
| 2023-04-20 | 2023-04-18 | 4 | King Simona | PASG | Common Stock | D | 6.250 | 6.250 | ||||||
| 2022-12-02 | 2022-12-01 | 4 | Kapadia Sandip | PASG | Common Stock | D | 1,1929 | -5.000 | -6 | 0 | ||||
| 2022-11-25 | 2022-11-22 | 4 | Fotopoulos Alexandros | PASG | Common Stock | D | 1,3300 | -3.720 | -5 | 20.245 | ||||
| 2022-11-25 | 2022-11-22 | 4 | Fotopoulos Alexandros | PASG | Common Stock | D | 12.500 | 23.965 | ||||||
| 2022-11-18 | 2022-09-19 | 4 | Toernsen Monika Maria | PASG | Common Stock | D | 1,5105 | -1.681 | -3 | 3.319 | ||||
| 2022-11-18 | 2022-09-15 | 4 | Toernsen Monika Maria | PASG | Common Stock | D | 5.000 | 5.000 | ||||||
| 2022-05-31 | 2022-05-26 | 4 | Woiwode Thomas | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-31 | 2022-05-26 | 4 | Porter Derrell | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-31 | 2022-05-26 | 4 | Kapadia Sandip | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-31 | 2022-05-26 | 4 | Islam Saqib | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-31 | 2022-05-26 | 4 | GOWEN MAXINE | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-31 | 2022-05-26 | 4 | Countouriotis Athena | PASG | Director Stock Option (Right to Buy) | D | 1,76 | 24.000 | 24.000 | |||||
| 2022-05-05 | 2022-05-04 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 1,9400 | 303.500 | 589 | 6.841.423 | ||||
| 2022-05-05 | 2022-05-03 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 1,9300 | 221.500 | 427 | 6.537.923 | ||||
| 2022-05-05 | 2022-01-20 | 4/A | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,0000 | 50.800 | 254 | 6.316.423 | ||||
| 2022-04-20 | 2022-04-18 | 4 | Forman Mark S | PASG | Employee Stock Options (right to buy) | D | 2,61 | 136.000 | 136.000 | |||||
| 2022-04-20 | 2022-04-18 | 4 | King Simona | PASG | Restricted Stock Unit | D | 25.000 | 25.000 | ||||||
| 2022-03-23 | 2022-03-21 | 4 | Goldsmith Bruce A | PASG | Common Stock | D | 3,1500 | 10.000 | 32 | 15.983 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Fotopoulos Alexandros | PASG | Stock Option (right to buy) | D | 4,52 | 163.900 | 163.900 | |||||
| 2022-02-14 | 2022-02-10 | 4 | Toernsen Monika Maria | PASG | Stock Option (right to buy) | D | 4,52 | 101.000 | 101.000 | |||||
| 2022-02-14 | 2022-02-10 | 4 | Salinas Eliseo Oreste | PASG | Stock Option (right to buy) | D | 4,52 | 157.500 | 157.500 | |||||
| 2022-02-14 | 2022-02-10 | 4 | King Simona | PASG | Stock Option (right to buy) | D | 4,52 | 159.000 | 159.000 | |||||
| 2022-02-14 | 2022-02-10 | 4 | Goldsmith Bruce A | PASG | Stock Option (right to buy) | D | 4,52 | 400.000 | 400.000 | |||||
| 2022-02-14 | 2022-02-10 | 4 | Cale Edgar B. | PASG | Stock Option (right to buy) | D | 4,52 | 106.000 | 106.000 | |||||
| 2022-01-24 | 2022-01-20 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,4200 | 369.100 | 2.001 | 6.634.723 | ||||
| 2022-01-20 | 2022-01-19 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,1100 | 43.300 | 221 | 6.265.623 | ||||
| 2022-01-20 | 2022-01-18 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,4600 | 114.700 | 626 | 6.222.323 | ||||
| 2022-01-20 | 2022-01-14 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,6000 | 10.300 | 58 | 6.107.623 | ||||
| 2022-01-13 | 2022-01-13 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,5200 | 41.800 | 231 | 6.097.323 | ||||
| 2022-01-13 | 2022-01-12 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,6500 | 100.000 | 565 | 6.055.523 | ||||
| 2022-01-13 | 2022-01-11 | 4 | ORBIMED ADVISORS LLC See Footnotes | PASG | Common Stock | I | 5,5300 | 8.200 | 45 | 5.955.523 | ||||
| 2021-12-10 | 2021-12-08 | 4 | Quigley Jill M. | PASG | Employee Stock Option (right to buy) | D | 0,23 | -60.782 | 27.626 | |||||
| 2021-12-10 | 2021-12-08 | 4 | Quigley Jill M. | PASG | Employee Stock Option (right to buy) | D | 0,23 | -11.193 | 3.729 | |||||
| 2021-12-10 | 2021-12-08 | 4 | Quigley Jill M. | PASG | Common Stock | D | 0,2300 | 71.975 | 17 | 368.754 | ||||
| 2021-08-25 | 2021-08-23 | 4 | King Simona | PASG | Employee Stock Option (Right to Buy) | D | 11,43 | 360.000 | 360.000 | |||||
| 2021-07-21 | 2021-07-19 | 4 | Toernsen Monika Maria | PASG | Restricted Stock Units | D | 20.000 | 20.000 | ||||||
| 2021-07-21 | 2021-07-19 | 4 | Toernsen Monika Maria | PASG | Employee Stock Option (Right to Buy) | D | 13,04 | 200.000 | 200.000 | |||||
| 2021-06-01 | 2021-05-27 | 4 | GOWEN MAXINE | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 4.542 | 4.542 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Woiwode Thomas | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Yamada Tadataka | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Islam Saqib | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Kapadia Sandip | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Ratcliffe Liam | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Porter Derrell | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 33.836 | 33.836 | |||||
| 2021-05-28 | 2021-05-27 | 4 | Countouriotis Athena | PASG | Director Stock Option (Right to Buy) | D | 13,83 | 16.918 | 16.918 | |||||
| 2021-05-21 | 2021-05-21 | 4 | Morris Richard Steven | PASG | Common Stock | D | 13,8183 | 2.171 | 30 | 5.454 | ||||
| 2021-05-21 | 2021-05-21 | 4 | Goldsmith Bruce A | PASG | Common Stock | D | 13,1150 | 2.000 | 26 | 5.983 | ||||
| 2021-05-19 | 2021-05-17 | 4 | Fotopoulos Alexandros | PASG | Restricted Stock Unit (RSU) | D | 50.000 | 50.000 | ||||||
| 2021-03-29 | 2021-03-22 | 4 | Salinas Eliseo Oreste | PASG | Restricted Stock Unit (RSU) | D | 60.000 | 60.000 | ||||||
| 2021-03-29 | 2021-03-22 | 4 | Salinas Eliseo Oreste | PASG | Restricted Stock Unit (RSU) | D | 40.000 | 40.000 | ||||||
| 2021-03-29 | 2021-03-22 | 4 | Salinas Eliseo Oreste | PASG | Employee Stock Option (Right to buy) | D | 18,85 | 275.000 | 275.000 | |||||
| 2021-03-17 | 2021-03-15 | 4 | Romano Gary | PASG | Employee Stock Option (right to buy) | D | 8,07 | -10.000 | 300.821 | |||||
| 2021-03-17 | 2021-03-15 | 4 | Romano Gary | PASG | Common Stock | D | 21,8616 | -1.617 | -35 | 0 | ||||
| 2021-03-17 | 2021-03-15 | 4 | Romano Gary | PASG | Common Stock | D | 20,9546 | -8.383 | -176 | 1.617 | ||||
| 2021-03-17 | 2021-03-15 | 4 | Romano Gary | PASG | Common Stock | D | 8,0700 | 10.000 | 81 | 10.000 | ||||
| 2021-02-22 | 2021-02-18 | 4 | GOWEN MAXINE | PASG | Stock Option (right to buy) | D | 21,46 | 33.836 | 33.836 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Quigley Jill M. | PASG | Stock Option (right to buy) | D | 21,85 | 105.000 | 105.000 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Morris Richard Steven | PASG | Stock Option (right to buy) | D | 21,85 | 50.000 | 50.000 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Romano Gary | PASG | Stock Option (right to buy) | D | 21,85 | 105.000 | 105.000 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Cale Edgar B. | PASG | Stock Option (right to buy) | D | 21,85 | 170.997 | 170.997 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Goldsmith Bruce A | PASG | Stock Option (right to buy) | D | 21,85 | 262.000 | 262.000 | |||||
| 2021-02-18 | 2021-02-16 | 4 | Fotopoulos Alexandros | PASG | Stock Option (right to buy) | D | 21,85 | 105.000 | 105.000 | |||||
| 2021-01-22 | 2021-01-20 | 4 | Quigley Jill M. | PASG | Common Stock | D | 30,0085 | -1.300 | -39 | 295.284 | ||||
| 2021-01-15 | 2021-01-14 | 4 | Quigley Jill M. | PASG | Common Stock | D | 30,1000 | 16.298 | 491 | 296.584 | ||||
| 2020-03-25 | 2020-03-24 | 4 | Countouriotis Athena | PASG | Common Stock | D | 14,9750 | 10.000 | 150 | 18.900 | ||||
| 2020-03-13 | 2020-03-03 | 4/A | Ratcliffe Liam By AI Passage LLC | PASG | Series B Preferred Stock | I | -2.066.630 | 0 | ||||||
| 2020-03-13 | 2020-03-03 | 4/A | Ratcliffe Liam | PASG | Common Stock | D | 18,0000 | 2.800 | 50 | 2.800 | ||||
| 2020-03-13 | 2020-03-03 | 4/A | Ratcliffe Liam By AI Passage LLC | PASG | Common Stock | I | 18,0000 | 550.000 | 9.900 | 2.616.630 | ||||
| 2020-03-13 | 2020-03-03 | 4/A | Ratcliffe Liam By AI Passage LLC | PASG | Common Stock | I | 2.066.630 | 2.066.630 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. By Versant Vantage I, L.P. | PASG | Series B Preferred Stock | I | -708.352 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. | PASG | Series A-2 Preferred Stock | D | -1.049.175 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. | PASG | Series A-1 Preferred Stock | D | -2.977.242 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. By Versant Vantage I, L.P. | PASG | Common Stock | I | 18,0000 | 225.000 | 4.050 | 933.352 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. By Versant Vantage I, L.P. | PASG | Common Stock | I | 708.352 | 708.352 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. | PASG | Common Stock | D | 1.049.175 | 4.026.417 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Versant Venture Capital VI, L.P. | PASG | Common Stock | D | 2.977.242 | 2.977.242 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Series B Preferred Stock | I | -541.002 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Series A-2 Preferred Stock | I | -1.311.469 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Series A-1 Preferred Stock | I | -3.721.552 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Common Stock | I | 541.002 | 5.947.323 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Common Stock | I | 1.311.469 | 5.406.321 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | ORBIMED ADVISORS LLC | PASG | Common Stock | I | 3.721.552 | 4.094.852 | ||||||
| 2020-03-03 | 2020-02-28 | 4 | ORBIMED ADVISORS LLC | PASG | Common Stock | I | 18,0000 | 373.300 | 6.719 | 373.300 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Series B Preferred Stock | D | -432.802 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Series A-2 Preferred Stock | D | -1.049.175 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Series A-1 Preferred Stock | D | -2.977.242 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Common Stock | D | 18,0000 | 550.000 | 9.900 | 5.009.219 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Common Stock | D | 432.802 | 4.459.219 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Common Stock | D | 1.049.175 | 4.026.417 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Frazier Life Sciences IX, L.P. | PASG | Common Stock | D | 2.977.242 | 2.977.242 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Series B Preferred Stock | I | -432.802 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Series A-2 Preferred Stock | I | -1.049.175 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Series A-1 Preferred Stock | I | -2.977.242 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Common Stock | I | 18,0000 | 550.000 | 9.900 | 5.009.219 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Common Stock | I | 432.802 | 4.459.219 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Common Stock | I | 1.049.175 | 4.026.417 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Heron Patrick J By Frazier Life Sciences IX, L.P. | PASG | Common Stock | I | 2.977.242 | 2.977.242 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Vantage I, L.P. | PASG | Series B Preferred Stock | I | -708.352 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Venture Capital VI, L.P. | PASG | Series A-2 Preferred Stock | I | -1.049.175 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Venture Capital VI, L.P. | PASG | Series A-1 Preferred Stock | I | -2.977.242 | 0 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Vantage I, L.P. | PASG | Common Stock | I | 18,0000 | 225.000 | 4.050 | 933.352 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Vantage I, L.P. | PASG | Common Stock | I | 708.352 | 708.352 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Venture Capital VI, L.P. | PASG | Common Stock | I | 1.049.175 | 4.026.417 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Woiwode Thomas By Versant Venture Capital VI, L.P. | PASG | Common Stock | I | 2.977.242 | 2.977.242 | ||||||
| 2020-03-03 | 2020-03-03 | 4 | Ratcliffe Liam | PASG | Common Stock | D | 18,0000 | 2.800 | 50 | 2.800 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Yamada Tadataka | PASG | Common Stock | D | 18,0000 | 6.500 | 117 | 656.149 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Kapadia Sandip | PASG | Common Stock | D | 18,0000 | 5.000 | 90 | 5.000 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Morris Richard Steven | PASG | Common Stock | D | 18,0000 | 400 | 7 | 400 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Quigley Jill M. By Spouse | PASG | Common Stock | I | 18,0000 | 1.000 | 18 | 1.000 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Quigley Jill M. | PASG | Common Stock | D | 18,0000 | 1.500 | 27 | 311.494 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Countouriotis Athena | PASG | Common Stock | D | 18,0000 | 8.900 | 160 | 8.900 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Fotopoulos Alexandros | PASG | Common Stock | D | 18,0000 | 5.500 | 99 | 5.500 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Goldsmith Bruce A | PASG | Common Stock | D | 18,0000 | 1.100 | 20 | 1.100 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Islam Saqib | PASG | Common Stock | D | 18,0000 | 5.000 | 90 | 5.000 | ||||
| 2020-03-03 | 2020-03-03 | 4 | Cale Edgar B. | PASG | Common Stock | D | 18,0000 | 2.000 | 36 | 2.000 | ||||
| 2020-03-02 | 2020-02-27 | 4 | Countouriotis Athena | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Woiwode Thomas | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Yamada Tadataka | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Heron Patrick J | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Islam Saqib | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 16.918 | 16.918 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Kapadia Sandip | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 16.918 | 16.918 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Ratcliffe Liam | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Morris Richard Steven | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 74.311 | 74.311 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Romano Gary | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 74.311 | 74.311 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Fotopoulos Alexandros | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 74.311 | 74.311 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Cale Edgar B. | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 99.731 | 99.731 | |||||
| 2020-03-02 | 2020-02-27 | 4 | SQUINTO STEPHEN P | PASG | Director Stock Option (Right to Buy) | D | 18,00 | 33.836 | 33.836 | |||||
| 2020-03-02 | 2020-02-27 | 4 | SQUINTO STEPHEN P | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 185.776 | 185.776 | |||||
| 2020-03-02 | 2020-02-27 | 4 | Quigley Jill M. | PASG | Employee Stock Option (Right to Buy) | D | 18,00 | 211.001 | 211.001 | |||||
| 2020-02-27 | 3 | Yamada Tadataka | PASG | Common Stock | D | 1.299.298 | ||||||||
| 2020-02-27 | 3 | Yamada Tadataka | PASG | Common Stock | D | 1.299.298 | ||||||||
| 2020-02-27 | 3 | Yamada Tadataka | PASG | Common Stock | D | 1.299.298 | ||||||||
| 2020-02-27 | 3 | SQUINTO STEPHEN P | PASG | Common Stock | D | 1.337.150 | ||||||||
| 2020-02-27 | 3 | SQUINTO STEPHEN P | PASG | Common Stock | D | 1.337.150 | ||||||||
| 2020-02-27 | 3 | SQUINTO STEPHEN P | PASG | Common Stock | D | 1.337.150 | ||||||||
| 2020-02-27 | 3 | Quigley Jill M. | PASG | Common Stock | D | 619.988 | ||||||||
| 2020-02-27 | 3 | Quigley Jill M. | PASG | Common Stock | D | 619.988 | ||||||||
| 2020-02-27 | 3 | Quigley Jill M. | PASG | Common Stock | D | 619.988 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
